Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Mol Biol Rep ; 51(1): 82, 2024 Jan 06.
Article in English | MEDLINE | ID: mdl-38183502

ABSTRACT

In today's culture, obesity and overweight are serious issues that have an impact on how quickly diabetes develops and how it causes complications. For the development of more effective therapies, it is crucial to understand the molecular mechanisms underlying the chronic problems of diabetes. The most prominent effects of diabetes are microvascular abnormalities such as retinopathy, nephropathy, and neuropathy, especially diabetes foot ulcers, as well as macrovascular abnormalities such as heart disease and atherosclerosis. MicroRNAs (miRNAs), which are highly conserved endogenous short non-coding RNA molecules, have been implicated in several physiological functions recently, including the earliest stages of the disease. By binding to particular messenger RNAs (mRNAs), which cause mRNA degradation, translation inhibition, or even gene activation, it primarily regulates posttranscriptional gene expression. These molecules exhibit considerable potential as diagnostic biomarkers for disease and are interesting treatment targets. This review will provide an overview of the latest findings on the key functions that miRNAs role in diabetes and its complications, with an emphasis on the various stages of diabetic wound healing.


Subject(s)
Atherosclerosis , Diabetes Mellitus , Diabetic Foot , Heart Diseases , MicroRNAs , Humans , Diabetic Foot/genetics , Diabetic Foot/therapy , Ulcer , MicroRNAs/genetics , RNA, Messenger
2.
Neurol Sci ; 43(1): 285-298, 2022 Jan.
Article in English | MEDLINE | ID: mdl-34032945

ABSTRACT

BACKGROUND: Numerous studies have indicated the role of inflammation in the pathogenesis of Alzheimer's disease (AD). However, the exact role of inflammatory markers in AD is still unclear. OBJECTIVE: The main objective of the current study was to find out the association between the level of inflammatory markers and AD. MATERIAL AND METHODS: The relevant articles have been extracted from PubMed as per the inclusion and exclusion criteria of the study. The mean value with standard deviation and number of participants in AD and control groups were extracted from relevant articles. The inverse variance was used as a statistical method and standard mean difference (SMD) as effect measure with 95% C.I. The random effect model was used and all analyses were done using Rev. Man 5.0. RESULTS: A total of 38 articles have been found relevant and selected for analysis. The overall estimate results have shown that the level of IL-6, TGF-ß1, and IL-1α were increased significantly in AD patients as compared to the control group among all other pro-inflammatory, inflammatory and anti-inflammatory mediators. CONCLUSION: The findings of the current study suggest that IL-6, TGF-ß1, and IL-1α may be a useful early marker in AD. However, further studies are required to confirm the exact utility of these inflammatory markers.


Subject(s)
Alzheimer Disease , Alzheimer Disease/drug therapy , Anti-Inflammatory Agents/therapeutic use , Biomarkers , Humans , Inflammation , Inflammation Mediators
3.
CNS Neurol Disord Drug Targets ; 22(10): 1403-1416, 2023.
Article in English | MEDLINE | ID: mdl-36443979

ABSTRACT

The S100 protein is one of the calcium-binding proteins associated with Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. S100 proteins are expressed in the central nervous system by oligodendrocytes, astrocytes and neurons during both normal and disease conditions. Although amyloid-beta aggregation and hyperphosphorylated tau plaques are the main pathological hallmarks of Alzheimer's disease, the S100 protein family is closely associated with neuroinflammation in several neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis in addition to various types of cancer and other brain diseases. This review aims to present the key role of S100 proteins and their different relevant isoforms, along with the various approaches used for the regulation of these proteins in several neurodegenerative disorders.


Subject(s)
Alzheimer Disease , Amyotrophic Lateral Sclerosis , Nervous System Diseases , Parkinson Disease , Humans , Alzheimer Disease/metabolism , Parkinson Disease/metabolism , S100 Proteins , Nervous System Diseases/drug therapy , tau Proteins/metabolism
4.
J Alzheimers Dis ; 94(s1): S187-S202, 2023.
Article in English | MEDLINE | ID: mdl-35848027

ABSTRACT

Parkinson's disease (PD) is the second most common neurodegenerative disease, affecting the elderly worldwide and causing significant movement impairments. The goal of PD treatment is to restore dopamine levels in the striatum and regulate movement symptoms. The lack of specific biomarkers for early diagnosis, as well as medication aimed at addressing the pathogenic mechanisms to decelerate the progression of dopaminergic neurodegeneration, are key roadblocks in the management of PD. Various pathogenic processes have been identified to be involved in the progression of PD, with mitochondrial dysfunction being a major contributor to the disease's pathogenesis. The regulation of mitochondrial functions is influenced by a variety of factors, including epigenetics. microRNAs (miRNAs) are epigenetic modulators involved in the regulation of gene expression and regulate a variety of proteins that essential for proper mitochondrial functioning. They are found to be dysregulated in PD, as evidenced by biological samples from PD patients and in vitro and in vivo research. In this article, we attempt to provide an overview of several miRNAs linked to mitochondrial dysfunction and their potential as diagnostic biomarkers and therapeutic targets in PD.


Subject(s)
MicroRNAs , Neurodegenerative Diseases , Parkinson Disease , Humans , Aged , MicroRNAs/genetics , MicroRNAs/metabolism , Parkinson Disease/drug therapy , Parkinson Disease/genetics , Neurodegenerative Diseases/pathology , Biomarkers/metabolism , Mitochondria/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL